Predictors of hot flushes in postmenopausal women who receive raloxifene therapy (2004)
- Authors:
- Autor USP: ALDRIGHI, JOSE MENDES - FSP
- Unidade: FSP
- DOI: 10.1016/j.ajog.2004.04.042
- Subjects: SINAIS E SINTOMAS (INDUZIDO QUIMICAMENTE;ETIOLOGIA); MENOPAUSA (EFEITOS DE DROGAS); HIDROCARBONOS AROMÁTICOS; HIDROCARBONOS AROMÁTICOS (EFEITOS ADVERSOS;APLICAÇÕES TERAPÊUTICAS); OSTEOPOROSE (QUIMIOTERAPIA)
- Language: Inglês
- Abstract: In a previous report, we described the results of a randomized, controlled trial that evaluated the potential of raloxifene to induce or exacerbate hot flushes. Here, we provide additional analyses that were undertaken to identify potential predictors of hot flushes and to assess the clinical usefulness of various therapeutic strategies for the reduction of hot flushes in postmenopausal women who receive raloxifene therapy. STUDY DESIGN: In this randomized, double-blind, placebo-controlled study, 487 unselected postmenopausal women were assigned randomly to receive treatment for 8 months with raloxifene, which was administered either at a dose of 60 mg/d every other day for 2 months followed by 60 mg/d (slow-dose escalation) or 60 mg/d throughout (raloxifene), or placebo. Data on the number, duration, intensity, and severity of hot flushes and awakenings because of night sweats were collected. Logistic regression models were used to examine the predictive value of various demographic and menopausal factors on the development or worsening of hot flushes. RESULTS: At baseline, 40.4 percent of all randomly assigned patients had hot flushes. The mean number of hot flushes (3-5 per week) was low. Fewer years postmenopause, surgical menopause, and previous estrogen or estrogen/progestin therapy were significant predictors of hot flushes at baseline but were not predictive of incident hot flushes during treatment with raloxifene. Of the women whoreceived raloxifene therapy who had pre-existing hot flushes at baseline, 36 percent women had none at the end point. Early postmenopause and surgical menopause were significant predictors of a biologically relevant increase in hot flushes (>/=14 flushes/week). Early postmenopause, previous estrogen/progestin therapy, high body mass index, and greater duration of hot flushes at baseline were significant predictors of the need for symptomatic treatment. ) After 2 months of treatment, women in early postmenopause had significantly more hot flushes with raloxifene therapy than with slow-dose escalation ( P = .042), whereas there was no significant difference between raloxifene therapy and slow-dose escalation among women in later postmenopause. In the 50 patients who requested symptomatic treatment during the study, phytohormones or veralipride did not reduce the number of hot flushes markedly
- Imprenta:
- Source:
- Título do periódico: American Journal of Obstetrics and Gynecology
- ISSN: 0002-9378
- Volume/Número/Paginação/Ano: v. 191, n. 6, p. 1979-1988, Dec. 2004
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
ALDRIGHI, José Mendes et al. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy. American Journal of Obstetrics and Gynecology, v. 191, n. 6, p. 1979-1988, 2004Tradução . . Disponível em: https://doi.org/10.1016/j.ajog.2004.04.042. Acesso em: 19 abr. 2024. -
APA
Aldrighi, J. M., Quail, D. C., Levy-Frebault, J., Aguas, F., Kosian, K., Garrido, L., et al. (2004). Predictors of hot flushes in postmenopausal women who receive raloxifene therapy. American Journal of Obstetrics and Gynecology, 191( 6), 1979-1988. doi:10.1016/j.ajog.2004.04.042 -
NLM
Aldrighi JM, Quail DC, Levy-Frebault J, Aguas F, Kosian K, Garrido L, Bosio-Le B, Saráchaga M, Graebe A, Niño AJ, Nickelsen T. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy [Internet]. American Journal of Obstetrics and Gynecology. 2004 ; 191( 6): 1979-1988.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1016/j.ajog.2004.04.042 -
Vancouver
Aldrighi JM, Quail DC, Levy-Frebault J, Aguas F, Kosian K, Garrido L, Bosio-Le B, Saráchaga M, Graebe A, Niño AJ, Nickelsen T. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy [Internet]. American Journal of Obstetrics and Gynecology. 2004 ; 191( 6): 1979-1988.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1016/j.ajog.2004.04.042 - Comparison between raloxifene and hormone replacement therapy on ambulatory blood pressure and arterial stiffness
- Efeitos da terapêutica de reposição hormonal transdérmica combinada e do raloxifeno sobre a proteína C reativa e anticorpos anti-LDL oxidada
- Efeito da terapia de reposição hormonal na complacência vascular em mulheres na pós-menopausa
- Efeitos do raloxifeno comparado a terapêutica de reposição hormonal contendo estradiol associado a progestógeno sobre a complacência vascular, em mulheres idosas com hipertensão arterial sistêmica
- Effects of hormone replacement therapy or raloxifene on ambulatory blood pressures and arterial stoffness in treated hypertensive postmenopausal women
- Papel da terapia da reposição hormonal I: lípide, glicose, distribuição da gordura corpórea e endotélio
- Prevenção primária da doença cardiovascular na mulher
- Cardiopatia na mulher
- Epidemiologia das doenças cardiovasculares nas mulheres
- Estado atual da terapêutica hormonal na peri e na pós-menopausa
Informações sobre o DOI: 10.1016/j.ajog.2004.04.042 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas